Compare Boston Scientific Corporation (BSX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs SYSCO Corporation — how do they compare? Boston Scientific Corporation trades at $51.63 (market cap $74.19B), while SYSCO Corporation trades at $84.76 (market cap $40.32B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and SYSCO Corporation pays a 2.61% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SYY | |
|---|---|---|
Market Cap | $74.19B | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $91.16 |
52-Week Low | $42.63 | $69.30 |
Enterprise Value | $86.27B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
SYY trades at $85.24, up 1.63% with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings of $1.53 EPS, beating estimates, with revenue growth to $81.37B in 2025. Analyst consensus is bullish with 60% buy ratings and an $88.25 price target. Recent news highlights CEO discussions on CNBC and positive earnings coverage.
Outlook remains positive with steady revenue growth and efficiency initiatives driving margins. Risks include competitive pressures and macroeconomic uncertainty. The stock offers value with a P/S of 0.48 and dividend yield support, but high P/B of 15.12 warrants caution on valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
